Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)—study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial

BACKGROUND: Since December 2019, SARS-CoV-2 virus has infected millions of people worldwide. In patients with COVID-19 pneumonia in need of oxygen therapy or mechanical ventilation, dexamethasone 6 mg per day is currently recommended. However, the dose of 6 mg of dexamethasone is currently being rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Maláska, Jan, Stašek, Jan, Duška, František, Balík, Martin, Máca, Jan, Hruda, Jan, Vymazal, Tomáš, Klementová, Olga, Zatloukal, Jan, Gabrhelík, Tomáš, Novotný, Pavel, Demlová, Regina, Kubátová, Jana, Vinklerová, Jana, Svobodník, Adam, Kratochvíl, Milan, Klučka, Jozef, Gál, Roman, Singer, Mervyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760569/
https://www.ncbi.nlm.nih.gov/pubmed/35033182
http://dx.doi.org/10.1186/s13063-021-05963-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760569/
https://www.ncbi.nlm.nih.gov/pubmed/35033182
http://dx.doi.org/10.1186/s13063-021-05963-6

Ejemplares similares